LOX and acute myeloid leukemia: Comparing LOX-high and LOX-low AML patients revealed a 3-year OS of 47% (95% CI 40–53%) and 53% (95% CI 48–58%, p = 0.022), and a 3-year EFS of 27% (95% CI 21–32%) and 35% (95% CI 30–40%, p = 0.005), respectively (Fig. 1a and b).